Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Axovant Sciences (NASDAQ:AXON) and BeiGene Ltd (NASDAQ:BGNE).
Axovant Sciences (AXON)
Cowen & Co. analyst Ritu Baral maintained a Hold rating on Axovant Sciences today. The company’s shares opened today at $2.10, close to its 52-week low of $1.02.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 31.1% and a 53.7% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
Currently, the analyst consensus on Axovant Sciences is a Hold with an average price target of $4.75.
See today’s analyst top recommended stocks >>
BeiGene Ltd (BGNE)
Cowen & Co. analyst Marc Frahm maintained a Buy rating on BeiGene Ltd today. The company’s shares opened today at $165.
According to TipRanks.com, Frahm is a 2-star analyst with an average return of 0.7% and a 45.5% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Adaptimmune Therapeutics, and Blueprint Medicines.
BeiGene Ltd has an analyst consensus of Strong Buy, with a price target consensus of $207.50, implying a 25.8% upside from current levels. In a report released today, Maxim Group also maintained a Buy rating on the stock with a $215 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
